Orbis Medicines Competitors and Similar CompaniesClear all

Orbis Medicines's competitors and similar companies include STADA, Faes Farma, Apeloa Pharmaceutical and Digi-Prex.

	Orbis Medicines Orbis Medicines is a company that develops a drug discovery platform.	STADA STADA Arzneimittel is a company engaged in the healthcare and pharmaceuticals business.	Faes Farma Faes Farma is a pharmaceutical company that develops, produces and commercializes pharmaceutical products and raw materials.	Apeloa Pharmaceutical Apeloa Pharmaceutical (普洛药业股份有限公司) is a company that develops and produces pharmaceutical products.	Digi-Prex Digi-Prex is a chronic disease management platform that provides a holistic solution to assist in the care of patients with chronic diseases.
Founding Date	Founding Date 2021	Founding Date 1895	Founding Date 1933	Founding Date 1989	Founding Date 2019
Type	Type Private	Type Public	Type Public	Type Public	Type Private
Tags	Tags Healthcare drug development healthtech pharma platform	Tags Healthcare drug development healthtech pharma	Tags Healthcare drug development healthtech pharma	Tags Healthcare drug development healthtech pharma	Tags Healthcare Technology drug development healthtech pharma platform
Locations	Locations Lausanne, CH HQ Copenhagen, DK	Locations Bad Vilbel, DE HQ Beijing, CN Hangzhou Shi, CN Shanghai, CN Bad Vilbel, DE Budapest, HU Vilnius, LT see more	Locations Leioa, ES HQ Madrid, ES Atlanta, US	Locations CN HQ	Locations HQ
Employees	Employees 363% increase	Employees 12,33911% increase	Employees 1,775	Employees 7,060	Employees 27
Valuation ($)	Valuation ($) N/A	Valuation ($) 6 b	Valuation ($) 1.2 b	Valuation ($) 2.7 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €3b (FY, 2020)	Revenue (est.) €493.6m (FY, 2024)	Revenue (est.) ¥9.7b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €1.3b (FY, 2020)	Cost of goods €167.1m (FY, 2024)	Cost of goods ¥7.2b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €1.7b (FY, 2020)	Gross profit €342.9m (FY, 2024)	Gross profit ¥2.5b (FY, 2025)	Gross profit N/A
Net income	Net income N/A	Net income €181.9m (FY, 2020)	Net income €111.1m (FY, 2024)	Net income ¥890.7m (FY, 2025)	Net income N/A
Funding
Latest funding round	Latest funding round $ 26m (about 2 years ago)	Latest funding round N/A	Latest funding round N/A	Latest funding round N/A	Latest funding round $ 5.5m (over 6 years ago)
Total funding raised	Total funding raised $ 26m	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 5.7m